ArticleBJOG : an international journal of obstetrics and gynaecology2026
SOX1/PAX1 Methylation for Triage of HPV-Positive Women in Cervical Cancer Screening: A Cohort Study.
Article in BJOG : an international journal of obstetrics and gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Additional Diagnostic Yield of Endocervical Curettage in Type 3 Transformation Zone for High-Grade Cervical Lesions: A Retrospective Analysis by Human Papillomavirus Genotype.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo establish a better triage strategy using SOX1/PAX1 methylation detection for high-risk HPV (hrHPV)-positive women than cytology.
designA cohort study.
settingPopulation-based cervical cancer (CC) screening cohort. POPULATION: A total of 5684 women were enrolled.
methodsSOX1/PAX1 methylation was detected by quantitative methylation-specific PCR using cytologic residue from hrHPV-positive women at baseline in a 3-year CC screening cohort. Risk stratification ability was evaluated by the immediate and cumulative cervical intraepithelial neoplasia (CIN) grade 2/3 or worse (CIN2+/3+) risks.
main outcome measuresCIN3+ and CIN2+.
resultsAt baseline, 682 hrHPV-positive women were included with 63 CIN2+ and 39 CIN3+. Over 3 years, 109 CIN2+ and 62 CIN3+ were detected. Methylation demonstrated better risk stratification than cytology among hrHPV-positive women. When compared with current practice triage strategy (Strategy A), post hoc re-triage analysis showed that methylation triage for all hrHPV-positive women (Strategy C) significantly increased sensitivity (97.44%/83.87% vs. 84.62%/64.52%, p = 0.0476/0.014), specificity (83.36%/85.00% vs. 73.41%/73.55%, p = < 0.001/< 0.001), positive predictive value (26.21%/35.86% vs. 16.18%/19.61%, p = 0.022/0.001), and negative predictive value (99.81%/98.14% vs. 98.74%/95.40%, p = 0.040/0.012) in detecting immediate and 3-year cumulative CIN3+. Similar improvements were observed for methylation triaged for HR12-positive (Strategy B) and for combined HPV and cytology primary screening (Strategy D). More importantly, all methylation-based triage strategies reduced colposcopies and postponed follow-up intervals compared to Strategy A over the 3-year period of CC screening.
conclusionSOX1/PAX1 methylation showed better risk stratification compared with cytology and enabled more efficient management of HPV-positive women, though external validation and head-to-head comparisons with other triage methods are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.